327 related articles for article (PubMed ID: 27347625)
1. Dosing, administration, and safety of radium-223: How I do it.
Dan TD; Doyle L; Raval AJ; Pridjian A; Gomella LG; Den RB
Can J Urol; 2016 Jun; 23(3):8301-5. PubMed ID: 27347625
[TBL] [Abstract][Full Text] [Related]
2. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
[TBL] [Abstract][Full Text] [Related]
3. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Nilsson S
Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
[TBL] [Abstract][Full Text] [Related]
4. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
Shore ND
Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
[TBL] [Abstract][Full Text] [Related]
5. Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
Vogelzang NJ
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):809-819. PubMed ID: 28649893
[TBL] [Abstract][Full Text] [Related]
6. Radium 223 dichloride for prostate cancer treatment.
Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
Wilson JM; Parker C
Expert Rev Anticancer Ther; 2016 Sep; 16(9):911-8. PubMed ID: 27501059
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
[TBL] [Abstract][Full Text] [Related]
9. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
Shirley M; McCormack PL
Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
[TBL] [Abstract][Full Text] [Related]
10. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
Vogelzang NJ; Coleman RE; Michalski JM; Nilsson S; O'Sullivan JM; Parker C; Widmark A; Thuresson M; Xu L; Germino J; Sartor O
Clin Genitourin Cancer; 2017 Feb; 15(1):42-52.e8. PubMed ID: 27613490
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
[TBL] [Abstract][Full Text] [Related]
12. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
13. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
16. Practical guide to the use of radium 223 dichloride.
Den RB; Doyle LA; Knudsen KE
Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
[TBL] [Abstract][Full Text] [Related]
17. Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):10-1. PubMed ID: 27167843
[No Abstract] [Full Text] [Related]
18. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C
Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557
[TBL] [Abstract][Full Text] [Related]
20. Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
Delacruz A; Arauz G; Curley T; Lindo A; Jensen T
Clin J Oncol Nurs; 2015 Apr; 19(2):E31-5. PubMed ID: 25840395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]